New treatment options for advanced pancreatic cancer

Final analysis of a randomized phase II study of bevacizumab (B) and gemcitabine (G) plus cetuximab (C) or erlotinib (E) in patients (pts) with advanced pancreatic cancer (PC)

(2017) H. L. Kindler et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study

(2008) B. Chauffert et al.   ANNALS OF ONCOLOGY

Gemcitabine based combination chemotherapy in advanced pancreatic cancer-indirect comparison

(2008) Asma Sultana et al.   BMC CANCER

Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses

(2008) A Sultana et al.   BRITISH JOURNAL OF CANCER

Cancer Statistics, 2008

(2008) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

FAK and IGF-IR interact to provide survival signals in human pancreatic adenocarcinoma cells

(2008) Weiguo Liu et al.   CARCINOGENESIS

Tissue Transglutaminase Regulates Focal Adhesion Kinase/AKT Activation by Modulating PTEN Expression in Pancreatic Cancer Cells

(2008) A. Verma et al.   CLINICAL CANCER RESEARCH

Phase II Trial of Curcumin in Patients with Advanced Pancreatic Cancer

(2008) N. Dhillon et al.   CLINICAL CANCER RESEARCH

Fluorouracil vs Gemcitabine Chemotherapy Before and After Fluorouracil-Based Chemoradiation Following Resection of Pancreatic Adenocarcinoma

(2008) William F. Regine et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Randomized Phase III Trial of Adjuvant Chemotherapy with Gemcitabine versus S-1 in Patients with Resected Pancreatic Cancer: Japan Adjuvant Study Group of Pancreatic Cancer (JASPAC-01)

(2008) A. Maeda et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study

(2008) Jean-Philippe Spano et al.   LANCET

Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies: Figure 1.

(2008) Jorge A. Garcia et al.   MOLECULAR CANCER THERAPEUTICS

Clinical evidence does not support the use of adjuvant radiotherapy in pancreatic cancer

(2008) John P Neoptolemos   Nature clinical practice. Oncology

Targeting PDGF Signaling in Carcinoma-Associated Fibroblasts Controls Cervical Cancer in Mouse Model

(2008) Rakesh K Jain et al.   PLOS MEDICINE